About SVB Leerink

Jeffrey A. Leerink is the Chief Executive Officer of SVB Leerink. Mr. Leerink is charged with defining, leading and executing the firm’s overarching business strategy and driving clarity, alignment and profitability across the entire business. Under Mr. Leerink’s leadership, the firm has grown to become a leading healthcare investment bank and company building partner.

Mr. Leerink founded Leerink Partners in 1995 and in 2019 merged the firm with SVB Financial Group, parent company to Silicon Valley Bank, to become SVB’s investment banking platform. The firm is focused on providing differentiated healthcare knowledge and equity capital markets, equity research and mergers and acquisitions expertise to help its clients define and achieve their strategic and capital markets objectives.

In 2008, Mr. Leerink co-founded and was a member of the Board of Directors of Humedica, Inc., a clinical intelligence company that was incubated at Leerink Partners. In 2013 the company was acquired by Optum, a subsidiary of UnitedHealth Group.

Mr. Leerink currently serves on the Board of Fog Pharmaceuticals. Additionally, he is a Board Director and the former Chairman of the Board at Big Brothers Big Sisters of Eastern Massachusetts. Mr. Leerink is a member of the Harvard Medical School Board of Fellows and is the Vice Chair of the New England Chapter of CEO’s Against Cancer.

Mr. Leerink holds a B.A. in Economics from Union College.

James (Jim) Boylan is the President and Head of Investment Banking at SVB Leerink and has 25 years of experience in healthcare investment banking. In addition to his integral role in the management and leadership of the firm, he also plays a very active role with many of the firm’s key client relationships.

Mr. Boylan joined the firm in 2009 as a Senior Managing Director and Head of Investment Banking charged with building the investment banking franchise. He was appointed to President in 2015. Prior to joining the firm, Mr. Boylan was a Managing Director at Merrill Lynch & Co. where he focused on healthcare clients and specialized in Mergers & Acquisition transactions. Mr. Boylan’s deal experience includes 200+ transactions where he has led or assisted in advising clients in the evaluation and successful execution of M&A and Capital Markets transactions across all sectors of the healthcare industry.

Mr. Boylan earned his M.B.A. from Columbia University in 1994 and a B.S. in Finance from Lehigh University in 1989.

Joseph Gentile is the Chief Administrative Officer at SVB Leerink.

Prior to joining the firm in 2007, Mr. Gentile served as the CFO for Lehman Brothers’ Global Investment Bank where he directed the accounting and financial needs within the Fixed Income division.  Prior to that, he served as CFO of the Global Corporate and Investment Bank at Bank of America, where he led the Capital Markets Division.  In addition he was the CFO for the Private Bank. Previously, Mr. Gentile spent more than 10 years with J.P. Morgan in various financial management positions, including Global Head of Financial Risk Management. He started his career at Arthur Andersen.

Mr. Gentile earned his B.S. in Accounting and his M.B.A. in Finance from St. John’s University.

Dan Dubin, M.D., is the Vice Chairman and Head of Biopharma Investment Banking at SVB Leerink and sits on the firm’s executive committee.

For over 20 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous financing, partnership, and M&A transactions for clients. Prior to joining the firm in 1999, Dr. Dubin co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. Preceding the founding of MEDACorp, he was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee.

Dr. Dubin serves as a director of Olivo Labs and has served as a director of Leerink Partners and Living Proof. Additionally he has served as Chairman of MetaWorks, which was sold to UBC in 2005. He also served as a member of the Science and Strategy Advisory Committee to GSK/Stiefel and an advisor to SKS Ocular.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Steven Heineman is the General Counsel and Senior Managing Director of the Compliance and Legal Department at SVB Leerink.

Prior to joining the firm in 2018, Mr. Heineman was the General Counsel at Convergex Group, LLC, a global brokerage and trading-related services provider. Before that, he was the General Counsel-Americas at Société Générale. Prior to being named General Counsel at SocGen, Mr. Heineman was the Director of Litigation & Regulatory Affairs.  Previously, Mr. Heineman practiced law at Debevoise & Plimpton LLP, where he specialized in complex commercial litigation, white collar criminal defense and regulatory enforcement matters.  He also served as a federal prosecutor in the Criminal Division of the United States Attorney’s Office for the Southern District of New York.

Mr. Heineman earned his B.A. degree in Political Science from Hobart College and his J.D. from New York University School of Law.

Jim Kelly is a Senior Managing Director, Director of Research at SVB Leerink. Mr. Kelly is responsible for product management, analyst development and equity strategy.

Prior to joining SVB Leerink in 2015, Mr. Kelly worked at Credit Suisse, where he served in research management as an Associate Director of Equity Research in New York and was responsible for leading key, strategic initiatives in research product and process development. Prior to his ADOR role at Credit Suisse, Mr. Kelly spent 13 years in Equity Research covering the US Pharmaceuticals industry for Lehman Brothers, Goldman Sachs and Credit Suisse First Boston.

Mr. Kelly received his M.B.A. from Columbia Business School and earned his B.S. in Mechanical Engineering from Lehigh University.  Mr. Kelly also serves on the board of the Lehigh Business School Dean’s Advisory Council.

Robert Leerink is a Senior Managing Director and Head of Institutional Equities at SVB Leerink.

Mr. Leerink has been with SVB Leerink since its inception in 1995. Prior to joining Institutional Sales team in 2000, Mr. Leerink led the Private Client Services group at the firm. Prior to SVB Leerink, Mr. Leerink worked in the Private Client Services division of Fechtor Detwiler.

Mr. Leerink holds a B.A. from Babson College.

Check the background of this investment professional on FINRA’s BrokerCheck.

Maura Polak is the Head of Human Resources at SVB Leerink. Ms. Polak has over 15 years of experience in Human Resources and leads all of SVB Leerink’s recruiting, employee relations, compensation and benefits initiatives.

Prior to joining the firm in 2004, Ms. Polak worked at Peer Review Analysis, a Division of Fortis, Inc., as a Human Resources Representative where she managed through a series of mergers, acquisitions and a divestiture.

Ms. Polak earned her B.A. in both Psychology and Spanish from Providence College.

Eric Anderson is a Managing Director and Chief Compliance Officer for SVB Leerink.

Prior to joining the firm in 2013, Mr. Anderson was the Chief Compliance Officer at Canaccord Genuity Inc. (and its predecessors) for seventeen years. Previously to that, he served as Director of Compliance at Wayne Hummer & Co. (and affiliates). He has over 35 years of experience in the financial industry and over 30 years in a compliance management role.

He earned a B.A. in Business Economics from the University of Illinois.

Robert Parente is a Managing Director at SVB Leerink and the Head of MEDACorp. For over 20 years, MEDACorp’s global network of healthcare professionals has served as a foundation of SVB Leerink’s differentiated guidance and assistance for its clients.

Mr. Parente joined SVB Leerink in 1995 as its first Equity Analyst. He was an analyst for approximately 10 years, covering Biotech, Pharma, Medtech and Diagnostic companies and then transitioned to the Investment Banking team where he was Head of Venture Capital Services. In this role, Mr. Parente introduced the VC community to SVB Leerink’s MEDACorp and Investment Banking services. In 2011, he became the Head of MEDACorp, the firm’s network of over 20,000 healthcare professionals, that expedite and differentiate its Equity Research and Investment Banking offerings. Prior to joining the firm, Mr. Parente worked for both Merrill Lynch and United Parcel Service.

He earned his undergraduate degree in Economics from Yale University.